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ABSTRACT 
INTRODUCTION 
Symptomatic mitral regurgitation patients have a poor prognosis unless treated by surgery. 49% of them 
are ineligible for surgical treatment due to contraindications or judged at high surgical risk by an 
interdisciplinary heart team and are left untreated. Percutaneous treatment with the MitraClip device 
is an alternative option for selected patients and has been proven to be safe and effective. The aim of 
this study is to describe our institution’s early results with implantation of the MitraClip and to compare 
them with other registries. 
 
METHODS 
A retrospective observational study was performed in the University Hospital of Lausanne. All patients 
treated with MitraClip in our institution between December 2012 and August 2018 were included in the 
study. Primary outcomes were all-cause mortality or unplanned hospitalization for heart failure at 2-
years and overall improvement in New York Heart Association functional class. Secondary outcomes 
included reduction in mitral regurgitation grade, change in left ventricular ejection fraction, 
periprocedural complications and adverse event within one month. 
 
RESULTS 
A total of 75 patients (72% men) underwent the Mitraclip implantation, mainly for functional mitral 
regurgitation (57%) of grade 3+ or 4+ (97%) with mean left ventricular ejection fraction of 44% and New 
York Heart Association functional class III or IV (73%). Acute device implantation was successful in 87% 
of cases. Periprocedural complications occurred in 24% of patients (3 patients with ischemic stroke and 
1 patient had a cardiac tamponade). At the time of discharge, there was an improvement in the New 
York Heart Association functional class (p<0.0001) with 51% of reduction of at least one functional class 
and 90% of patients had mitral regurgitation ≤ 2+ (p<0.0001). Left ventricular ejection fraction was not 
significantly different than baseline (p=0.48). In the first month post-implantation follow-up, 
complications occurred in 14% of patients (1 patient died at 11 days after a hemorrhagic stroke and 1 
patient had an ischemic stroke). Within 2-year, all-cause mortality was 28% with 85% of non-cardiac 
cause, 24% needed readmission for heart failure and 4.0% had a mitral valve surgery.  
 
CONCLUSION 
In the University Hospital of Lausanne, the MitraClip procedure for patients with mitral regurgitation 
and at high surgical risk is a safe and effective alternative facilitating the reduction of mitral regurgitation 
and improving functional capacity. Primary and secondary outcomes are similar to those observed in 
other registries (ACCESS-EU study, TCVT registry and TRAMI registry). 
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INTRODUCTION 
Mitral regurgitation (MR) is the second most frequent valvular heart disease in the developed countries 
(1). Its prevalence in the United States population is 1.7% and increases with age to reach 9.3% of people 
over 75 years old (2).  
MR results in a lack of coaptation between anterior and posterior leaflets of the mitral valve during 
systole, allowing the blood to flow back in the left atrium instead of flowing from the left ventricle 
through the aortic valve (3). The European Society of Cardiology (ESC) has issued guidelines that classify 
the origin of MR as either primary (degenerative), when one or several components of the valve 
apparatus are directly affected or secondary (functional), when remodeling occurs in the left ventricle 
due to ischemic or dilated cardiomyopathy (4).  
Leakage increase blood volume and pressure in the left atrium that tends to enlarge and may develop 
atrial fibrillation. If regurgitation is severe, blood volume and pressure increase in pulmonary veins, 
lungs and right heart and can lead to lungs congestion or heart failure with associated symptoms 
(dyspnea, shortness of breath at night or during exercise, fatigue, edema in the legs or ankles, decrease 
in appetite, cough…). In some case, patients, may be asymptomatic for years, despite severe 
regurgitation.  
Severe symptomatic MR without surgical treatment is associated with 5% of mortality per year and 
reach 60% at 5 year if associated with heart failure (5). There are no medications indicated to treat MR, 
but some are used to manage symptoms of heart failure or rhythm abnormalities (4). Surgical treatment 
(mitral valve repair or replacement) is the primary treatment for severe MR and/or symptomatic 
patients. Nevertheless, 49% symptomatic patients with severe MR are not eligible for surgery due to 
advanced age, left ventricular dysfunction or comorbidities (6).  
Edge-to-edge leaflet repair technique, developed by Alfieri in the early 1990s, is a surgery that consists 
in suturing between the anterior and posterior leaflet to create a double-orifice valve during diastole 
and a better approximation of the leaflets during systole, thereby reducing the MR (7). Based on this 
technique, a percutaneous device, the MitraClip (Abbott, Menlo Park, CA, USA) has been developed and 
is an alternative to surgery for patients at high surgical risk (8).  
The EVEREST I trial (Endovascular Valve Edge-to-Edge Repair Study) demonstrated the feasibility and 
the safety of this treatment (9) and the EVEREST II trial, a multicenter randomized controlled trial which 
compared percutaneous repair versus surgery in operable patients, proved its efficacy (10). The device 
has been approved in Europe under the CE mark since 2008 and by the US FDA in 2012. Since then, 
several studies established that there is a low incidence of mortality and hospitalization for heart failure 
and significant improvements in functional status (11). ESC 2017 guidelines recommend the 
percutaneous edge-to-edge repair in patients with symptomatic degenerative MR who are at high 
surgical risk or inoperable and have been discussed by a heart team (class IIB), while in patients with 
functional MR and left ventricular ejection fraction < 30% who remain symptomatic despite optimal 
medical management, conservative (medical therapy) or palliative (catheter-based and surgery) 
treatment is evaluated by a heart team (class IIB)(4).  
Introduced in 2012 in the University Hospital of Lausanne, this technique is currently the only alternative 
to non-eligible patients for a mitral surgery.  
Objectives are to describe our institution’s early results with implantation of the MitraClip and to 
compare them with other registries.  
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METHODS 
Study design 
A retrospective observational study (category A) was performed in the University Hospital of Lausanne. 
All patients treated with MitraClip in our institution between December 2012 and August 2018 were 
included in the study. Demographic information, preoperative evaluation, intraoperative and 
postoperative data about each patient were collected until October 2018 to create a database. 
 
Patient selection 
Patients with symptomatic grade 3+ or greater MR despite optimal therapy, referred to our institution 
for consideration of MitraClip implantation were discussed by a heart team including surgeons, 
interventional cardiologists and imaging specialists to decide the optimal treatment for each patient. All 
of them classified as being at high risk to undergo a mitral surgery were candidates for device 
implantation. An initial evaluation that included a transthoracic echocardiography (TTE) and a 
transesophageal echocardiography (TEE) was performed to quantify MR and to characterize anatomic 
feasibility of MitraClip implantation.  
 
Operative procedure 
The MitraClip procedure is performed under general anesthesia and with echocardiographic and 
fluoroscopic guidance. After establishing a femoral venous access, an atrial transseptal puncture is 
performed in the upper portion of the fossa ovalis, 4-5 cm above the valve coaptation line, and a 24-Fr 
steerable guide is passed into the left atrium. The clip delivery system is advanced through the guide to 
introduce the MitraClip in the left atrium. The MitraClip is positioned with arms perpendicular to the 
line of coaptation of the valve leaflets and advanced into the left ventricle with arms opened to 120°. 
Then, the MitraClip is gradually pulled back towards the left atrium grasping the leaflets and closed to 
20°. TEE is performed to ensure that both leaflets are appropriately inserted and secure within the clip 
and to analyze the MR reduction and pressure gradients. Once the assessments are positive, the clip 
arms are closed. Additional clips may be placed to optimize MR reduction if there was no residual mitral 
stenosis. At the end of the procedure, the system is withdrawn and antiplatelet therapy is instituted.  
 
Outcomes and definition of variables 
Primary outcomes of interest were all-cause mortality or unplanned hospitalization for heart failure at 
2-years and overall improvement in New York Heart Association (NYHA) functional class after 
implantation. Unplanned hospitalization for heart failure included all admissions in the emergency 
department or hospitalizations in a medical/cardiologic unit for the treatment of all cause heart failure. 
NYHA functional class was used to assess subjectively the patient’s functional capacity. Secondary 
outcomes included reduction in MR grade, change in left ventricular ejection fraction (LVEF), 
periprocedural complications and adverse event within one month. MR grade is classified in 1+ (mild), 
2+ (moderate), 3+ (moderate-to-severe) and 4+ (severe) using a transthoracic echocardiography 
according to American Society of Echocardiography recommendations. Acute device success was 
defined as residual MR ≤ 2+ after clip implantation and minimum 1 clip implanted.  
 
Statistical analysis 
Data analysis was done using Microsoft Excel (version 16.17). Categoric variables are expressed as 
percentages. Continuous variables are presented as mean ± standard deviation or as median 
(interquartile range, IQ25, IQ75). The Student’s unpaired t test was used to compare continuous 
variables. Kaplan-Meier curves were constructed to study survival and absence of hospitalizations for 
heart failure. P value < 0.05 were considered significant. 
 
Ethical considerations 
The project was approved by the Cantonal (VD) Ethic Committee on research involving humans and was 
conducted in accordance with the Declaration of Helsinki. All participants signed informed consent.  
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RESULTS 
Patient characteristics 
From December 11, 2012, through August 3, 2018, a total of 75 patients underwent Mitraclip 
implantation. The baseline characteristics of all patients are shown in Table 1. 
The mean age of the study population was 77 ± 10 years, 42% of the patients were aged 80 years or 
more. 90% of patients presented at least one comorbidity and 92% had cardio-vascular risk factors. The 
mean logistic EuroSCORE II (European System for Cardiac Operative Risk Evaluation) at baseline, which 
allows the calculation of the risk of death after a heart operation, was 6.1 ± 4.4%.  
The majority of the patients had severe symptoms of heart failure, with 73% in NYHA functional class III 
or IV. The mean LVEF was 44 ± 16%, with 22% of patients with LVEF < 30%, 42% of patients between 
30-50% and 36% with LVEF > 50%. Etiology of regurgitation was functional in 57% of patients and 
degenerative in 30%. In 13% the etiology was mixed. MR grade was ≥ 3+ in 97% of the patients.  
Table 1. Characteristics of the Patients at Baseline    
Characteristics CHUV, Lausanne 
Clinical 1   
Age, yr 77 ± 10  
Male sex, % 72  
Diabetes, % 19  
Hypertension, % 77  
Hypercholesterolemia, % 50  
Body-mass index 2, kg/m2 25 ± 4.5  
Previous percutaneous coronary intervention, % 45  
Previous coronary-artery bypass grafting, % 18  
Previous stroke or transient ischemic attack, % 12  
Peripheral vascular disease, % 13  
History of atrial fibrillation or flutter, % 50  
Previous implantation of pacemaker/defibrillator, % 19  
Chronic obstructive pulmonary disease, % 19  
Obstructive sleep apnea syndrome, % 13  
Kidney failure, % 31  
EuroSCORE II 3, % 6.1 ± 4.4  
Related to heart failure 4   
NYHA class, % (no./total no.)   
I 1.3 (1/77)  
II 26 (20/77)  
III 64 (49/77)  
IV 9.1 (7/77)  
Echocardiographic data 4   
Left ventricular ejection fraction, % 44 ± 16  
Mechanism of mitral regurgitation, % (no./total no.)   
Functional 57 (44/77)  
Degenerative 30 (23/77)  
Mixed 13 (10/77)  
Severity of mitral regurgitation, % (no./total no.)   
grade 2+ to 3+ 2.6 (2/77)  
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grade 3+ 16 (12/77)  
grade 3+ to 4+ 3.9 (3/77)  
grade 4+ 78 (60/77)  
Effective regurgitant orifice area, mm2 45 ± 23  
1 75 patients underwent MitraClip implantation and 78 device implantations were attempted. Therefore, 78 patients’ data in 
total were considerate. Plus-minus values are mean ± SD. NYHA = New York Heart Association. 
2 The body-mass index is the weight in kilograms divided by the square of the height in meters. 
3 European System for Cardiac Operative Risk Evaluation (EuroSCORE) which allows the calculation of the risk of death after a 
heart operation, range from 0 to 100% with higher percentages indicating greater risk. 
4 One patient had a tricuspid regurgitation in whom MitraClip was attempted. His clinical data were included in the statistical 
analysis but those related to heart failure, echocardiographic data and follow-up were not included.  
 
Data on the procedure 
A total of 78 device implantations were attempted. On average, procedural time was 154 ± 63 minutes, 
radiation time 44 ± 23 minutes, and 1.6 ± 0.7 clips were implanted. One clip was implanted in 45% of 
cases, 2 clips were implanted in the majority of cases (47%) and a few patients received 3 or more clips 
(5.1%). 2 patients (2.6%) had no clip implanted, one patient had an abdominal venous perforation with 
transseptal puncture needle at the beginning of the procedure resulting in a hemoperitoneum without 
active bleeding seen on the CT scan after the procedure and one because the clip made a trans-mitral 
gradient of 8 mmHg, resulting in a mitral stenosis. A MitraClip was attempted in a patient with tricuspid 
regurgitation but failed because of a persistent regurgitation despite four clips which made a transaortic 
gradient of 20 mmHg. Among the 77 patients in whom echocardiography was performed after the clip 
implantation, MR grade was 1+ in 32 patients (42%), grade 1+ to 2+ in 20 patients (26%), grade 2+ in 17 
patients (22%), grade 2+ to 3+ in 3 patients (3.9%), grade 3+ in 2 patients (2.6%) and grade 4+ in 3 
patients (3.9%) (Figure 1), which was a significantly improvement compared with baseline (p<0.0001).  
 
Acute device implantation, defined as residual MR ≤ 2+ after MitraClip implantation and minimum 1 clip 
implanted, was successful in 87% of cases. 19 patients of the 78 procedures (24%) had periprocedural 
complications (Table 2). 4 patients had potentially severe complications during procedure; 3 patients 
had an ischemic stroke, 2 with full recovery at the time of discharge from hospital, and one patient 
required a pericardiocentesis due to cardiac tamponade that occurred during transseptal puncture 
without needing cardiac surgery. 6 patients had atrial septum defect with bidirectional shunt between 
both atriums that required a closure device. 2 patients had intestinal lesions as a result of 
transesophageal echocardiography that needed gastroscopy after the procedure; one patient had 
bleeding of cardia with 5 clips needed to control the bleeding and the other one had esophagus 
hematoma. Partial detachment of the clip that grasped only on one leaflet occurred in one patient. This 
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Figure 1. Mitral regurgitation at baseline and at the time of 
discharge
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patient had no embolization of the clip after the hospitalization. No cases of death and no patients 
required urgent heart surgery 24-hours after MitraClip implantation.  
Table 2. Periprocedural Complications and Adverse Events within 1 Month   
Variable CHUV, Lausanne 
Periprocedural complications during device implantation, no./total no.1 (%)  
Device-implantation failure 2/78 (2.6) 
Death  0/78 (0) 
Stroke 3/78 (3.8) 
Tamponade/pericardiocentesis 1/78 (1.3) 
Urgent conversion to heart surgery 0/78 (0) 
Hemorrhage resulting in transfusion 2 2/78 (2.6) 
New-onset atrial fibrillation 0/78 (0) 
Deep venous thrombosis at the femoral venous access 1/78 (1.3) 
Atrial septum lesion or atrial septal defect 6/78 (7.7) 
Partial detachment of the clip 1/78 (1.3) 
Gas embolism in coronary artery 1/78 (1.3) 
Intestinal lesion 2/78 (2.6) 
Adverse Events within 1 month after device implantation, no./total no.3 (%)  
Death  1/74 (1.3) 
Stroke 2/74 (2.7) 
Heart surgery 0/74 (0) 
Hemorrhage resulting in transfusion 0/74 (0) 
New-onset cardiac rhythm abnormalities 4/74 (5.4) 
Respiratory infection 3/74 (4.0) 
Partial detachment of the clip 1/74 (1.3) 
1 78 represents the number of patients in whom device implantation was attempted. 
2 Hemorrhage that required blood transfusion (more than two units of packed red blood cells). 
3 Adverse events data of 74 patients were available within one month. 
 
Follow-up data 
At the time of discharge from hospital, assessments of the functional capacity were available for 45 
patients (Figure 2). Of these patients, 23 (51%) had a reduction in NYHA functional class; 8 patients 
(18%) had NYHA functional class I, 19 (42%) NYHA functional class II, 17 (38%) NYHA functional class III 
and 1 (2.2%) NYHA functional class IV, which was significantly different from the previous values (mean 
NYHA functional class 2.24 ± 0.61 vs 2.81 ± 0.77 at baseline, p<0.0001). Left ventricular ejection fraction 
was 42 ± 16%, not significantly different than baseline (44 ± 16%, p=0.48). 
During hospitalization and in the first month post-implantation follow-up, complications occurred in 10 
patients (14%) of 74 patients (Table 2). One patient had a hemorrhagic stroke at 4 days after the 
procedure and died at 11 days and one patient had an ischemic stroke at 2 days. 3 patients had 
nosocomial pneumonia.  
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Clinical follow-up about mortality within 1-year was obtained in 57 patients with a follow-up rate of 98% 
(17 patients had not yet completed the 1-year follow-up) and the estimated 1-year mortality was 8.2%. 
At two years, 13 (28%) of 47 patients died, 11 (85%) of non-cardiac cause and 2 (15%) of a cardiac origin, 
on average during the thirteenth month (Figure 3). 11 (24%) of 45 patients needed readmission due to 
heart failure, which occurred, on average, in the fourth month (Figure 4). A total of 3 (4.0%) patients 
had to repeat MitraClip procedures after the first implantation, one patient at 17 days because of an 
abdominal venous perforation without clip implanted, one patient at 3 months because of a partial 
dehiscence at 9 days with a chordae tendineae rupture and one patient at 19 months because of an 
anterior leaflet tear. 3 (4.0%) of 75 patients underwent mitral valve repair or replacement after the 
MitraClip implant procedure. 
 
1,30
17,78
25,97
42,22
63,64
37,78
9,09
2,22
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
NYHA at baseline (n=77) NYHA at the time of discharge
(n=45)
Pa
tie
nt
s,
 %
Figure 2. New York Heart Association (NYHA) functional class at 
baseline and at the time of discharge from hospital. 
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Figure 3. Kaplan-Meier curve estimates of survival at 24 months (n=47)
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Figure 4. Kaplan-Meier curve estimates absence of unplanned hospitalization for 
heart failure at 24 months (n=45)
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DISCUSSION 
The aim of this study was to expose the University Hospital of Lausanne early results with implantation 
of MitraClip and compare them with results reported in registries. First, the high acute procedural 
success (87%), the rate of periprocedural complications (24%) and the 1-month incidence of all adverse 
event (14%) confirms that the MitraClip procedure is reasonably safe. Complete detachment or 
embolization of the clip were not reported. Furthermore, mortality within one year was 8.2% and within 
two years 28%, mostly (85%) related to non-cardiac causes, reflecting the patients’ baseline 
comorbidities. Second, the reduction in MR grade ≤ 2+ (90%) and improvement in functional class in > 
50% of patients proved the short term efficacity of MitraClip. In addition, about 75% patients that 
underwent a clip needed no readmission for heart failure at two years, which means that efficacity 
persists throughout the years. 
In the following, results will be compared with the initial EVEREST II cohort (12) and the 3 largest series 
of MitraClip patients published so far: the ACCESS-EU (ACCESS-Europe, A Two-Phase Observational 
Study of the MitraClip System in Europe), a prospective non-randomized study that enrolled 567 
patients in 14 centers in Germany, Italy and Denmark in 2013 (13), the Transcatheter Valve Treatment 
Sentinel Pilot Registry (TCVT registry), a prospective independent study that enrolled 628 patients 
treated in 25 centers in 8 European countries in 2014 (14) and the Transcatheter Mitral Valve 
Interventions (TRAMI registry), a prospective and retrospective non-randomized study that enrolled 828 
patients in 21 German sites in 2015 (15).  
Patients’ demographics information and preoperative evaluation are very similar to those observed in 
registries (13)(14)(15). In concordance with these registries, our results show that patients who 
nowadays benefit from an implantation reflect a higher risk profile than those enrolled in the EVEREST 
II clinical trial (12). Patients included in our registry were older (mean age 77 ± 10 vs 67.0 ± 12.7 years), 
in more advanced stages of heart failure (NYHA functional class III or IV in 73% vs 50.0%), mainly with 
lower LVEF (44 ± 16 vs 59.9 ± 10.1%) and often with functional valve disease (57% vs 27.0%). While 
EVEREST II trial enrolled operable patients, patients receiving a MitraClip in reality are those judged 
ineligibles for surgery due to their high-risk level. Logistic EuroSCORE II was 6.1 ± 4.4%, lower than 
logistic EuroSCORE I observed in previous registries (ACCESS-EU 23.0 ± 18.3%, TCVT registry 20.4 ± 
16.7%, TRAMI registry 20%). This finding may be explained by the fact that EuroSCORE II had better 
predictive discrimination for operative mortality than EuroSCORE I, which greatly overestimated this 
risk (16) and that other adverse factors, like oncological context or patients’ fragility often seen in 
patients treated in our institution, were not taken into account in the risk score calculation.  
Despite the higher risk at baseline, results of acute procedural success, with clip implantation rate (97% 
vs 96.0% in EVEREST II trial) and immediate achievement of MR grade 2+ or lower in 90% (71.8% in 
EVEREST II trial), are substantially better than those in the early EVEREST II involving patients at high risk 
of surgical mortality (10). Notably, acute procedural success was similar to contemporary registries (87% 
vs 91.2% in ACCESS-EU, 95.4% in TCVT registry and 94.0% in TRAMI registry). It reflects probably the 
operator’s increased experience with implantation over time. Grasso and al. have examined the device 
implantation time and have demonstrated a learning curve in the overall experience (17). Even though 
this high acute procedural success rate is achieved, almost one quarter of patients remain highly 
symptomatic (NYHA functional class III or IV) at the time of discharge. Further research must identify 
which clinical or procedural characteristics are predictive of such a poor clinical response. 
LVEF was not significantly different at the time of discharge from the hospital (42 ± 16% vs 44 ± 16% at 
baseline, p=0.48). MR is only one of the multiple mechanisms that lead to left ventricle dilatation in 
patients with functional MR, as most cases in this report, and may explained the reason of steady LVEF 
after implantation of the clip.  
Periprocedural complications and adverse event within one month (respectively 24% and 14%) in our 
registry was higher than other publications, most likely driven by strictness of variables and definitions 
or by advanced age patients with a high burden of comorbidities. The incidence of specific 
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periprocedural complications was comparable with no case of dead (no case in ACCESS-EU, 0.1% in 
TRAMI registry), stroke rate of 3.8% (no case in ACCESS-EU) and cardiac tamponade rate of 1.3% (0.9% 
in ACCESS-EU, 1.1% in TCVT, 1.7% in TRAMI registry). The incidence of major adverse event within one 
month was also comparable with mortality of 1.3% (3.4% in ACCESS-EU, 2.9% in TCVT registry, 4.5% in 
TRAMI registry), stroke rate of 2.7% (0.7% in ACCESS-EU, 0.2% in TCVT registry, 0.8% in TRAMI registry).  
One-year mortality was 8.2%, slightly lower than in ACCESS-EU (17.3%), TCVT registry (15.3%) and 
TRAMI registry (20.3%). Re-hospitalization due to heart failure (22%) during the first year after MitraClip 
implantation was similar to TCVT registry (22.8%) and TRAMI registry (14.1%). The incidence of repeat 
mitral valve procedures became necessary in 8.0% of patients (9.7% in ACCESS-EU, 3.8% in TCVT, 8.5% 
in TRAMI registry), half of them were surgical interventions and the other half were repeated MitraClip 
procedures. In contrast, EVEREST II trial had 21% of repeated mitral valve procedures and all of them 
were surgical reinterventions. Such results show the technical experience and growing knowledge in 
MitraClip interventions.  
No differences were made between degenerative and functional MR in this report. Chiarito and al. (18) 
have reported that patients with functional MR have a significantly higher functional class (NYHA 
functional class III or IV) and a higher rate of rehospitalization for heart failure at one year after a 
MitraClip implantation, meaning that functional and degenerative MR are two conditions that differ 
from each other and that they may have variable treatment.  
New multicenter randomized controlled trials have compared transcatheter mitral-valve repair plus 
optimal medical therapy and optimal medical therapy alone in patients with functional MR. Published 
in August 2018, MITRA-FR trial (the Multicentre Study of Percutaneous Mitral Valve Repair MitraClip 
Device in Patients With Severe Secondary Mitral Regurgitation), involving patients with severe 
secondary MR and LVEF < 40%, demonstrated that despite its apparent safety and efficacy, the MitraClip 
does not improve patients’ prognosis with no significative difference of death or unplanned 
hospitalization for heart failure at 1 year between groups (19). These results suggest that poor prognosis 
is related to underlying cardiac disease, rather than mitral insufficiency which is probably only a marker 
of severity of the disease. In contrast, the COAPT trial (the Cardiovascular Outcomes Assessment of the 
MitraClip Percutaneous Therapy), involving patients with heart failure and moderate-to-severe or 
severe functional MR, published in September 2018, demonstrated a lower rate of hospitalization for 
heart failure, lower mortality and better quality of life and functional capacity with transcatheter mitral 
valve repair than with medical therapy alone within 2 years of follow-up (20). Different results between 
the two trials likely relate to patient selection, medication changes during the trial, level of operator 
experience and the outcomes achieved, as well as duration of follow-up. RESHAPE-HF (A Randomized 
Study of the MitraClip Device in Heart Failure Patients with Clinically Significant Functional Mitral 
Regurgitation), a similar trial, must add some clarity to explain the very different results between MITRA-
FR and COAPT trials. 
Study limitations 
First, this study was limited because data collection was retrospective. A large amount of follow-up data 
on functional status or echocardiographic outcomes were missing at the time of the database creation. 
For example, functional capacity at the time of discharge from the hospital was not often reported. 
Therefore, results are subject to selection bias. Second, this is a relatively small patient population. 
Third, a proportion of patients was not yet eligible for the 2-year follow-up at the time of the data 
analysis.  
CONCLUSIONS 
The MitraClip procedure in the University Hospital of Lausanne for patients with MR and at high surgical 
risk appeared to be a safe and effective alternative facilitating the reduction of mitral regurgitation and 
improving functional capacity. Primary and secondary outcomes are similar to those observed in other 
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registries. To complete and confirm results obtained further studies have to demonstrate the 
improvement of MR, functional status at 1-year or more after the procedure in our institution. 
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